

アジア太平洋経済協力（APEC）ワークショップ出席について

アジア太平洋経済協力（APEC）ワークショップ開催（インドネシア、バリ島平成 25 年 9 月 3 日）に際して、APEC から横倉会長への招待に応じ、会長の指示により石井常任理事が出席した。APEC では、加盟 21 か国の持続的発展を支援するために 2010 年に「APEC 域内中小企業の商業倫理戦略」を立ち上げ、医療関連部門において、今後この地域の患者への最善の医療提供を行うに際し、倫理面からの検討を行う場を設けた。今回のワークショップは「医療機器及びバイオ医薬品セクターにおける倫理環境の育成」をテーマとして開催され、セッション 2「医療セクターにおける高い倫理水準の確保：病院、患者、そして産業界の協力の重要性」において、石井常任理事がコメンテーターとして、世界医師会のジュネーヴ宣言、ヘルシンキ宣言等における医の倫理規定の下で、ソウル宣言に定めたプロフェSSIONナル・オートノミーに則り、医療提供者として医療に従事していることを述べた。なお、当ワークショップの成果物として声明（別紙 1）が採択された。

1. 会 期：平成 25 年 9 月 3 日（火）
2. 場 所：ザ・ウェスティン・リゾート・ヌサドゥア、バリ島、インドネシア
3. 会議名：アジア太平洋経済協力（APEC）ワークショップ
「医療機器及びバイオ医薬品セクターにおける倫理環境の育成」
4. 参加者：石井常任理事
5. プログラム
9 月 3 日（火）
セッション 1 倫理基準と実績の向上における APEC のリーダーシップ
セッション 2 医療セクターにおける高い倫理水準の確保／病院、患者、
産業界の協力の重要性
セッション 3 倫理的医療環境の構築における政府の役割の理解
詳細版（別紙 2）

APEC 医療利害関係者ハイレベル会議

医療機器およびバイオ医薬品セクターにおける倫理環境の育成

インドネシア、ヌサドゥア、2013年9月3日

声 明

アジア太平洋経済協力 (APEC) に加盟する21の国と地域において、医療機器およびバイオ医薬品セクターにおける倫理的な商行為を育成するイニシアチブの認識度を高め、促進することが私たちの共通の目標である。APEC域内の医療提供者、専門機関、汚職取締機関、保健省、保健監督機関、保健関連政府調達機関、バイオ医薬品および医療機器団体、民間の医療会社の代表として、インドネシア政府保健省とインドネシア州共同組合・中小企業省からの招待を受け、また「APEC域内中小企業の商業倫理に関するイニシアチブ」の共同出資による経済活動の一環として、2013年9月3日、インドネシアのヌサドゥアで会合を行った。

命や健康を守る安全で効果的、かつ高品質な医療技術や治療法が広く普及するには、産業と医療提供者、そして政府の倫理的な協力が必要であると考えます。さらに、患者のニーズに合った革新的な医療技術や治療法を開発する上でも、倫理的な協力は不可欠である。密接に連携し、医療産業における倫理的な商行為を強化するにはどうしたらよいか、これまでも話し合いを続けてきた。

「経済成長や市民の安全にとって、あるいはAPEC域内の経済や投資面での連携を強化する上で、汚職こそが大きな障害である」「民間セクターにおける行動規範を入念に作り上げたり、汚職に対する対策、とりわけ政府、企業、その他の利害関係者間の相互関係における倫理的な商行為を促進する対策を講じたりするためには、企業や官民のパートナーシップが重要な役割を果たす」。2012年にAPEC首脳によって採択された以上のような声明を我々は支持する。

また、医療機器産業における自主的倫理規範に関するクアラルンプール原則、およびバイオ医薬品産業における自主的倫理規範に関するメキシコシティ原則を支持するという点でも一致している。このようにハイレベルな原則を展開するために、産業界、政界、および市民団体から成る専門家作業部会を招集し、当該原則の実行に向けた初期の能力強化資金を調達する上で、APEC およびその中小企業作業部会がリーダーシップを発揮したことに感謝する。

クアラルンプール原則およびメキシコシティ原則（“APEC 原則”）を作成し、承認することは、医療産業における持続可能な経済成長を促進する上で重要な第一歩であったという点で、我々の意見は一致している。また、医療提供者やその分野の専門機関、上級保健監視官、保健省職員、汚職取締職員、健康製品およびサービスの調達機関、および産業界のリーダーとして、我々には自らの経済活動や APEC 域内で倫理的な医療環境をさらに普及させる責任があるということにも合意した。この取り組みは、経済連携を促進するために APEC が取り組む主要ミッションのなかでも、基礎になるものだと認識している。なぜならば、持続可能な経済成長にとって人々の健康は不可欠なものであると同時に、経済が発展し、人々が高齢化するに連れて、医療にかかわる製品やサービスが貿易や経済活動に占める割合も高まっていくからである。

したがって、倫理的な医療環境を促進する上で、利害関係者それぞれが重要な役割を担うという事は明らかである。

保健医療関連企業は、適用されるあらゆる法律や法令に従うだけでなく、APEC 原則などの高い倫理水準にも従わなければならない。これは、救命や健康増進のための医療技術や治療法を開発し、患者に提供するという自らの使命の一部である。

医療提供者およびその分野の専門機関は、患者の利益最優先で行動する責任がある。また、あらゆる利害関係者との相補的な活動や対話を通じて、APEC 原則などの倫理原則に則った相互関係の重要性を伝えるという、重要な役割を認識しなければならない。

保健省および保健監督機関は、産業界における倫理規範の価値を認識すると同時に、あらゆる利害関係者が APEC 原則などの倫理原則と、国や地域の産業界における倫理規範を支持するように働きかけなければならない。

政府および民間調達団体は、透明性があり、倫理的かつ明確な政策、プロセスおよび手順に則って、医療にかかわる製品やサービスを調達しなければならない。

汚職取締機関は、明文化された法律を客観的に適用し、法的処置を補完するものとして産業界が行う自主規制を歓迎しなければならない。また、すべての企業が APEC 原則などの同一な倫理原則や、国および地域の産業界における倫理規範に適合し、それらを順守するように働きかけなければならない。

我々は、能力強化や対話、高水準な支援を継続的に行っていくことが、取り組みの不断の発展にとって非常に重要であることに合意した。

そのため、ハイレベルの「APEC 商業倫理に関する公開討論会」を新たに継続的に開催することによって「APEC 域内中小企業の商業倫理に関するイニシアチブ」を制度化

するよう APEC に求めた。この取り組みは、多様な手段で地域の連携を発展させることを目的としており、新たに起こりつつある商業倫理の課題への対策として、能力強化やベストプラクティスの共有、あらゆる利害関係者の対話などが含まれる。また、倫理的な商行為を強化する上で、あらゆる利害関係者の役割を強化することも目指している。そのような公開討論会を開催することにより、中小企業の運営が持続可能になり、グローバルなサプライヤーとして活躍できるような、外部に対するビジネス環境と内部的な企業環境が育成されるであろう。また、倫理的な協力を行うことで、革新的な医療技術や治療法の開発が支援されるだけでなく、命や健康を守る医療技術や治療法が、患者にとって利用しやすくなる。

背景

APEC で開催される公開討論会は、経済に関するものとしてはこの地域では初めてで、アジア太平洋地域および APEC の 21 の国と地域における経済成長や経済協力、貿易、投資を促進する数多くのイニシアチブをリードしている。「APEC 域内中小企業の商業倫理」に関するイニシアチブは、2010 年に発足し、商業倫理の自主規範の指針となる APEC 原則の作成を支持してきた。対象となったのは、当該地域の中小企業にとって非常に重要な産業で、医療機器およびバイオ医薬品産業も含まれている。安全かつ効果的な医療技術や治療法を利用しやすいものにする、中小企業のイノベーションを促進すること、あるいは中小企業による輸出品の信頼性を高めるというだけでなく、最終的には患者の利益を最優先にした決定がなされるためにも、医療産業における倫理的協力関係の強化は不可欠である。

2011 年、専門家作業部会によって草案の作成から仕上げまでが行われ、APEC 各国の首脳、大臣、および中小企業の代表者によって承認された医療機器産業における自主的倫理規範に関するクアラルンプール原則、およびバイオ医薬品産業における自主的倫理規範に関するメキシコシティ原則は、各国政府および医療専門機関を含むすべての利害関係者に対し、各国の産業界と調整し、それぞれの条件に合った倫理的協力関係を促進することを求めている。2012 年、APEC 各国の首脳は、前述の APEC 原則に沿った倫理規範を普及させるために協力し、政府、企業およびその他の利害関係者間における倫理的協力関係を促進することを提唱した。

APEC Healthcare Stakeholders Awareness High-Level Meeting:

Fostering Ethical Environments in the Medical Device and Biopharmaceutical Sectors

Nusa Dua, Indonesia – 3 September 2013

STATEMENT

With the common goal of building awareness and promoting support for initiatives to foster ethical business practices in the medical device and biopharmaceutical sectors across the 21 Asia Pacific Economic Cooperation (APEC) member economies, we – representatives from healthcare providers and professional organizations, anti-corruption agencies, health ministries, health regulatory agencies, health-related government procurement agencies, biopharmaceutical and medical device associations, and private healthcare companies from across the APEC region – met in Nusa Dua, Indonesia, on 3 September 2013 by joint invitation of the Ministry of Health and Ministry of Cooperatives and SMEs of the Government of Indonesia and by the co-sponsoring economies of the “Business Ethics for APEC SMEs Initiative.”

We recognize that ethical collaboration among industry and healthcare providers and governments promotes broad patient access to life-saving and health-enhancing medical technologies and therapies that are safe, effective and of high quality. Further, we recognize that ethical collaboration is essential to the development of new innovative medical technologies and therapies that meet patient needs. We continued our dialogue about how we can work closely together to strengthen ethical business practices in the healthcare sector.

We affirmed the statements made by APEC Leaders in 2012 that corruption is “...a tremendous barrier to economic growth, the safety of citizens, and to the strengthening of economic and investment cooperation among APEC economies” and that: “we recognize the important role of business and public-private partnerships in promoting the elaborating of codes of conduct in the private sector and measures to fight corruption, especially measure that support the promoting of ethical business practices in interactions between government, business and other stakeholders.”

We also affirmed our support for The Kuala Lumpur Principles for Voluntary Codes of Ethics in the Medical Device Sector as well as The Mexico City Principles for Voluntary Codes of Ethics in the Biopharmaceutical Sector. We acknowledged APEC and its SME Working Group for its leadership in convening expert working groups composed of industry, government and civil society to develop these high standard principles and for providing initial capacity building funds to begin to have them implemented.

We agreed that the creation and endorsement of The Kuala Lumpur Principles and The Mexico City Principles (“the APEC principles”) was an important first step toward promoting sustainable economic growth in the medical sector. We also agreed that as leaders of healthcare provider and professional organizations, senior health regulators and health ministry officials, anti-corruption officials, health products and services procurement agencies, and industry we have a responsibility to take further steps together to promote an ethical health care environment in our economies and in the APEC region. We noted that this work is fundamental to APEC’s core mission of promoting economic cooperation because healthy populations are the foundation of sustainable economic growth and health care products and

services account for a growing share of international trade and economic activity as economies develop and as populations age.

We therefore established that each stakeholder has a unique and important role to promote ethical health care environments:

Healthcare Companies should follow high ethical standards, such as the APEC principles, as well as all applicable laws and regulations, as part of their mission to help patients by developing and making life-saving and health-enhancing medical technologies and therapies available.

Healthcare Providers and Professional Organizations have a duty to act in the best interests of patients and recognize the importance of their role in communicating the importance of interactions based on ethical principles, such as the APEC principles, including through complementary activities and ongoing dialogue with all stakeholders.

Health Ministries and Health Regulatory Agencies should recognize the value of industry codes of ethics and encourage all stakeholders to support ethical principles, such as the APEC principles, and national and local industry codes of ethics.

Government and Private Procurement Entities should procure health products and services based on transparent, ethical, clear, and accountable policies, processes and procedures.

Anti-corruption Authorities should objectively apply clear laws, welcome industry self regulation as complementary to law enforcement, and encourage all companies to adopt and adhere to uniform ethical principles, such as the APEC principles, and national and local industry codes of ethics.

We agreed that sustained capacity building, dialogue, and high level support are crucial to ensuring continued progress.

We therefore called on APEC to institutionalize the “Business Ethics for APEC SMEs Initiative” by creating an ongoing, high-level “APEC Business Ethics Forum” to foster regional cooperation through multiple avenues, including capacity building, best practice sharing, and multi-stakeholder dialogue to address new and emerging business ethics challenges and the role of all stakeholders in strengthening ethical business practices. Such a forum would foster an external business environment and internal company environment that will permit SMEs to operate on a sustainable basis and serve as global suppliers. Ethical collaborations will also promote patient access to life-saving and health-enhancing medical technologies and therapies, as well as support the development of new innovative medical technologies and therapies.

Background

The Asia-Pacific Economic Cooperation (APEC) forum is the region’s premier economic forum, leading numerous initiatives that facilitate economic growth, cooperation, trade and investment in the Asia-Pacific region and among its 21 member economies. Launched in 2010, the “Business Ethics for APEC SMEs” initiative has championed the creation of APEC principles for voluntary codes of business ethics in several sectors of significant importance to SMEs in the region, including the medical device and biopharmaceutical sectors. Heightened ethical interactions in these healthcare sectors are crucial to

enhancing patient access to safe and effective medical technologies and therapies, promoting SME innovation, building SME export confidence, and ultimately ensuring that decisions are made in the best interest of patients.

Drafted and finalized by expert working groups in 2011 and endorsed by APEC Leaders, APEC Ministers, and APEC SME Ministers The Kuala Lumpur Principles for Voluntary Codes of Ethics in the Medical Device Sector and The Mexico City Principles for Voluntary Codes of Ethics in the Biopharmaceutical Sector call upon all stakeholders, including governments and healthcare professional organizations, to coordinate with their local industries to advance ethical collaborations consistent with their provisions. In 2012, APEC Leaders called for collaborations to propagate codes of ethics aligned with these APEC principles to promote ethical interactions between government, business, and other stakeholders.



Asia-Pacific
Economic Cooperation



APEC Healthcare Stakeholders Awareness High-Level Meeting: Fostering Ethical Environments in the Medical Device & Biopharmaceutical Sectors

Nusantara Room 3 | The Westin Nusa Dua | Bali, Indonesia | 3 September 2013

-- MEETING PROGRAM --

TIME	MEETING PROGRAM
08:00-08:30	Registration
08:30-08:40	<p>Welcome Remarks</p> <p>A. A. Gde Agung, <i>Regent of Badung</i></p> <p>H.E. Syarifuddin Hasan, <i>State Minister for Cooperatives & SMEs, Indonesia</i></p>
08:40-08:45	<p>Meeting Overview</p> <p>Ms. Lynn Costa, Senior Trade Development Advisor, U.S. Department of Commerce <i>Project Overseer, Business Ethics for APEC SMEs Initiative</i></p>
08:45-9:00	<p>APEC Leadership in Business Ethics for the Medical Device and Biopharmaceutical Sectors</p> <p>Dr. Wimonkan Kosumas, Deputy Director General, Office of SMEs Promotion, Thailand <i>Chair of the APEC SME Working Group</i></p>
Session One	APEC Leadership in Heightening Ethical Standards & Results Achieved Thus Far (60 Minutes)
09:00-10:00	<p>APEC Leadership in Heightening Ethical Standards <i>This session will provide a brief overview of: why APEC launched the "Business Ethics for APEC SMEs" initiative; how the initiative has involved experts from government, industry, and academia/civil society; outcomes thus far (The KL Principles and The Mexico City Principles for voluntary codes of ethics for industry); and an identification of the challenges and opportunities that remain to fostering ethical environments in the healthcare sector.</i></p> <p>Moderator: Ms. Lynn Costa, Senior Trade Development Advisor, U.S. Dept of Commerce <i>Project Overseer, Business Ethics for APEC SMEs Initiative</i></p> <p>Dato' Hafsah Hashim, Chief Executive Officer of SME Corporation, Malaysia <i>Co-Chair of the Expert Working Group to Draft the Kuala Lumpur Principles</i></p> <p>Mr. Ivan Ornelas Diaz, Director of International Relations, Ministry of Economy of Mexico <i>Co-Chair of the Expert Working Group to Draft the Mexico City Principles</i></p> <p>Mr. Chris White, Executive Vice President & General Counsel, AdvaMed (United States)</p>



	<p><i>Co-Chair of the Expert Working Group to Draft the Kuala Lumpur Principles</i></p> <p>Mr. Russell Williams, President, Rx&D (Canada) <i>Co-Chair of the Expert Working Group to Draft the Mexico City Principles</i></p> <p><i>Ten Minutes Per Discussant -- Twenty Minutes for Q&A /Discussion</i></p>
10:00-10:15	Coffee Break
Session Two	Ensuring a High Standard of Ethics in the Healthcare Sector: The Importance of Hospitals, Physicians, and Industry Collaboration (75 Minutes)
10:15 - 11:30	<p>Learning from Success: Examples of Cooperation Among Hospitals/Physician Groups and Industry</p> <p>Moderator: Mr. Chris White, Executive Vice President & General Counsel, AdvaMed <i>Co-Chair of the Expert Working Group to Draft the Kuala Lumpur Principles</i></p> <p><u>Discussion Leads (10 Minute Opening Remarks):</u></p> <p>Mr. Mario Mongilardi Fuchs, Vice President, Lima Chamber of Commerce, Peru</p> <p>Dr. Andreas Loeffler, Chair Professional Development and Standards and Mr. Adrian Cosenza, Chief Executive Officer, Australian Orthopaedic Association</p> <p><u>Discussants (3 Minute Opening Remarks):</u></p> <p>Ms. Sabrina Chan, Executive Director, The Hong Kong Association of the Pharmaceutical Industry (HKAPI)</p> <p>Mr. Li Hongshan, Executive Vice President & Secretary General, China Hospital Association</p> <p>Dr. Masami Ishii, Executive Board Member, Japan Medical Association</p> <p><i>45 minutes for Q&A/Discussion</i></p>
Session Three	Understanding the Role of Governments in Creating an Ethical Healthcare Environment: Learnings from Across the APEC Region (60 Minutes)
11:30 – 12:30	<p>The Role of Government in Encouraging a High Standard of Ethics in the Healthcare Sector</p> <p>Moderator: Dato' Hafsah Hashim, Chief Executive Officer of SME Corporation, Malaysia <i>Co-Chair of the Expert Working Group to Draft the Kuala Lumpur Principles</i></p> <p><u>Discussion Leads (10 Minute Opening Remarks):</u></p> <p>Dato' Hajjah Sutinah Binti Sutan, Deputy Chief Commissioner (Prevention), Malaysian Anti-Corruption Commission (MACC)</p> <p>Dr. Kenneth Hartigan-Go, Acting Director General, Food & Drug Administration, Philippines</p> <p>Professor Agus Purwadianto, Senior Advisor, Ministry of Health, Indonesia</p> <p>Dr. Somsak Lolekha, President, Medical Council of Thailand</p> <p><u>Discussants (3 Minute Opening Remarks):</u></p> <p>Mr. Chu Kung-Mao, Director-General, Agency Against Corruption, Ministry of Justice, Chinese Taipei</p> <p>Ms. Lee Hui Keng, Acting Assistant Group Director, Pre-Marketing Division, Health Products Regulation Group, Health Sciences Authority, Singapore</p>



**Asia-Pacific
Economic Cooperation**



	<i>15 minutes for Q&A/Discussion</i>
12:30 - 13:30	Luncheon <i>Location: Portraits Restaurant (located in The Westin Nusa Dua)</i>
13:30 - 15:00	<p>Concurrent Breakout Session One: Launching Local Action Plans for Ethical Interactions in the Biopharmaceutical Sector (90 Minutes)</p> <p>Description: Small breakout group will discuss strategies for launching local action plans that heighten ethical interactions among healthcare stakeholders and that support the effective implementation of industry codes of ethics aligned with the APEC Principles.</p> <p>Facilitated by:</p> <p>Mr. Ivan Ornelas Diaz, Director of International Relations, Ministry of Economy of Mexico <i>Co-Chair of the Expert Working Group to Draft the Mexico City Principles</i></p> <p>Mr. Russell Williams, President, Rx&D (Canada) <i>Co-Chair of the Expert Working Group to Draft the Mexico City Principles</i></p>
13:30 - 15:00	<p>Concurrent Breakout Session Two: Launching Local Action Plans for Ethical Interactions in the Medical Device Sector (90 Minutes)</p> <p>Description: Small breakout group will discuss strategies for launching local action plans that heighten ethical interactions among healthcare stakeholders and that support the effective implementation of industry codes of ethics aligned with the APEC Principles.</p> <p>Facilitated by:</p> <p>Dato' Hafsah Hashim, Chief Executive Officer of SME Corporation, Malaysia <i>Co-Chair of the Expert Working Group to Draft the Kuala Lumpur Principles</i></p> <p>Mr. Chris White, Executive Vice President & General Counsel, AdvaMed (United States) <i>Co-Chair of the Expert Working Group to Draft the Kuala Lumpur Principles</i></p>
15:00 - 15:30	Coffee Break
15:30 - 16:30	<p>Report to the APEC SME Working Group and APEC SME Ministers: Crafting a "Nusa Dua Statement on Fostering Ethical Environments in the Healthcare Sector" (60 Minutes)</p> <p>Facilitated by:</p> <p>Mr. Russell Williams, President, Rx&D (Canada) <i>Co-Chair of the Expert Working Group to Draft the Mexico City Principles</i></p> <p>Dato' Hafsah Hashim, Chief Executive Officer of SME Corporation, Malaysia <i>Co-Chair of the Expert Working Group to Draft the Kuala Lumpur Principles</i></p>
16:30-17:00	<p>Closing Remarks (30 Minutes)</p> <p>Ms. Lynn Costa, APEC Project Overseer & Senior Trade Development Advisor, U.S. Department of Commerce</p>
17:30 - 19:00	Reception <i>Location: Temple Garden (located in The Westin Nusa Dua)</i>



**Asia-Pacific
Economic Cooperation**



**APEC Healthcare Stakeholders Awareness High-Level Meeting:
Fostering Ethical Environments in the Medical Device & Biopharmaceutical Sectors**

The Westin Resort Nusa Dua | Bali, Indonesia | 3 September 2013

FINAL PARTICIPANT LIST

Confirmed Participants: 63

Confirmed APEC Economies: 17

AUSTRALIA
<p>Professor Nicholas J. Talley, President-Elect <i>The Royal Australasian College of Physicians (RACP)</i></p> <p>Dr. Andreas Loeffler, Chair Professional Development and Standards <i>Australian Orthopaedic Association Limited</i></p> <p>Mr. Adrian Cosenza, Chief Executive Officer <i>Australian Orthopaedic Association Limited</i></p>
BRUNEI DARUSSALAM
<p>Mr. Wee Shyue Liang <i>Pharmacist Ministry of Health</i></p>
CANADA
<p>Mr. Russell Williams, President & Co-Chair of the Expert Working Group to Draft the Mexico City Principles <i>Canada's Research-Based Pharmaceutical Companies (Rx&D)</i></p>
CHILE
<p>Ms. Macarena Guarda Maillet <i>General Directorate for International Economic Relations</i></p> <p>Ms. Claudia Valenzuela Arellano <i>Women's National Service of Chile</i></p>
CHINA
<p>Mr. Li Hongshan, Executive Vice President & Secretary General <i>China Hospital Association</i></p>



**Asia-Pacific
Economic Cooperation**



Mr. Joseph Cho, Managing Director
RDPAC (R&D Based Pharmaceutical Association Committee)

HONG KONG, CHINA

Ms. Sabrina Chan, Executive Director
Member of the APEC Public-Private Implementation Group, Biopharmaceutical Sector
The Hong Kong Association of the Pharmaceutical Industry (HKAPI)

Professor Fok Tai-Fai, Vice President (General Affairs)
The Hong Kong Academy of Medicine

Mr. Harry Chan, Senior Research and Trade Practices Officer
Hong Kong Consumer Council

INDONESIA

Professor Agus Purwadianto, Senior Adviser
MOH Technology and Globalization, Ministry of Health

Mr. Titah Sihdjati Riadhie
GAKESLAB Indonesia

Mr. Budi Prasety
GAKESLAB Indonesia

Mr. Parulian Simanjuntak, Executive Director
International Pharmaceutical Manufacturers Group (IPMG)

Ms. Endang Toekinun, Staff Regional Health
Centre International Cooperation, Ministry of Health

Ms. Sheila Kadir, Head of subdivision Regional Health 1
Centre International Cooperation, Ministry of Health

Ms. Hardini Kusumadewi, Staff Regional Health
Centre International Cooperation, Ministry of Health

Ms. Budi Dhewajani, Director of Centre International Cooperation
Ministry of Health

Mr. Doddy Izwardy, Head of Division Regional Health, Centre International Cooperation
Ministry of Health



**Asia-Pacific
Economic Cooperation**



Ms. Arianti Anay, Director of Medical Device Production and Distribution Service
Ministry of Health

Mr. Hari Nurcahyo, Country General Manager
BD (BECTON DICKINSON ASIA LTD.)

Mr. Wahid Kurniawan, Commercial Compliance Champion
BD (BECTON DICKINSON ASIA LTD.)

I Wayan Dipta, Deputy Minister of R&D for Cooperatives and SMEs Resources
Ministry of Cooperatives and SMEs

Martono Djohari
Ministry of Cooperatives and SMEs

Ms. Yulia Purwarini
National Agency of Drug and Food Control

JAPAN

Dr. Masami Ishii, Executive Board Member
Japan Medical Association

Mr. Yuji Noto, Manager, International Affairs Division
Japan Medical Association

Mr. Bruce Ellsworth, Director of Government Affairs
Johnson & Johnson Japan

MALAYSIA

Dato' Hafsah Hashim, CEO
SME Corp. Malaysia

Dato' Hjh. Sutinah binti Sutan, Deputy Commissioner for Prevention
Malaysian Anti-Corruption Commission (MACC)

Ms. Junipah binti Wandu, Chief Senior Assistant Commissioner
Malaysian Anti-Corruption Commission (MACC)

Miss Mayamin Haini Musa, Assistant Manager
International Cooperation Secretariat, SME Corp

Mr. Ahmad Mu'izz Mohd Yusof, Legal Advisor
SME Corp. Malaysia



**Asia-Pacific
Economic Cooperation**



Ms. Fara Zalina Mohamed, Legal Advisor
SME Corp. Malaysia

Mayamin Haini, Assistant Manager
SME Corp Malaysia

Farhana AlKhatib, Manager
SME Corp Malaysia

MEXICO

Mr. Ivan Ornelas Diaz, Director of International Relations &
Co-Chair of the Expert Working Group to Draft the Mexico City Principles
Mexican Ministry of Economy

PERU

Mr. Mario Mongilardi, Vice President
Lima Chamber of Commerce

Ms. Virginia Baffigo, President
EsSalud

PHILIPPINES

Dr. Kenneth Hartigan-Go, Acting Director General
Food & Drug Administration, Philippines

Dr. Edgardo Fernando, Chairman, Professional Regulatory Board of Medicines
Professional Regulation Commission (PRC)

SINGAPORE

Ms. Lee Hui Keng, Acting Assistant Director for the Pre-Marketing Division & Director (Covering)
for the Complementary Health Products Branch, Health Products Regulation Group
Health Sciences Authority, Singapore

Mr. Abdul Luheshi, Vice President
Health Care Compliance & Privacy, Janssen, Asia Pacific

CHINESE TAIPEI

Mr. Chu Kung-Mao, Director-General



**Asia-Pacific
Economic Cooperation**



Agency Against Corruption (AAC)

Ms. Fan Yi-Kai, Agent
Agency Against Corruption (AAC)

Mr. Chang Han-Shu, Officer
Agency Against Corruption (AAC)

Ms. Chen Ying-Ching, Second Secretary
Taipei Economic and Trade Office in Jakarta

Dr. Min-Huei Hsu, Counselor, Office of International Cooperation
Ministry of Health and Welfare

Mr. Lu Su-Wei, Director of Civil Service Ethics Office
Ministry of Economic Affairs

THAILAND

Dr. Wimonkan Kosumas, APEC SME Working Group Chair & Deputy Director General
Office of SMEs Promotion

Ms. Nipawis Ritthironk, Senior Operational Officer
Office of SMEs Promotion

Dr. Somsak Lolekha, President
Medical Council of Thailand

Dr. Wonchat Subhachaturas, President
Medical Association of Thailand

Pol. Col. Pokpibul Potranan, Secretary General
Office of Public Sector Anti-Corruption Commission (Ministry of Justice)

Pol. Lt. Col. Terdsak Putson, Director, Bureau of the Suppression of Corruption in Public Sector
Office of Public Sector Anti-Corruption Commission (Ministry of Justice)

UNITED STATES

Ms. Lynn Costa, Project Overseer, Business Ethics for APEC SMEs Initiative
International Trade Administration, U.S. Department of Commerce

Mr. Chris White, Executive Vice President & General Counsel
The Advanced Medical Technology Association (AdvaMed)



**Asia-Pacific
Economic Cooperation**



VIETNAM

Mr. Do Minh Hung, Deputy Director-General, Drug Registration Division
Drug Administration of Vietnam (DAV), Ministry of Health

Mr. Nguyen Minh Tuan, Director-General
Department of Medical Equipment & Construction, Ministry of Health

Ms. Nguyen Phuong Lan, Deputy Director, SOE Reform Division, Agency for Enterprise Development
Ministry of Planning and Investment

BUSINESS ETHICS FOR APEC SMEs SECRETARIAT

Ms. Patricia Wu

** APEC economies not represented at this meeting are: Republic of Korea, New Zealand, Papua New Guinea and Russia.*